Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus - Wikidata - wikimedia - TriplyDB

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

http://www.wikidata.org/entity/Q34177087

about

Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway Type I interferonopathies in pediatric rheumatology IL-1α/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy.Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases Pathways leading to an immunological disease: systemic lupus erythematosus.Type I interferon in the pathogenesis of lupus.Shared signatures between rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome uncovered through gene expression meta-analysis.Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus.Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome.Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis.Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study.Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.Therapies in Aicardi-Goutières syndrome.Advances in understanding the role of type I interferons in systemic lupus erythematosus.Targeting interferons in systemic lupus erythematosus: current and future prospects.Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.CD4+ T-Cell Profiles and Peripheral Blood Ex-Vivo Responses to T-Cell Directed Stimulation Delineate COPD Phenotypes.High-throughput RNA sequencing reveals distinct gene signatures in active IgG4-related disease.Novel biomarkers for systemic lupus erythematosus.Development of a Validated Interferon Score Using NanoString Technology.

P2860

Q26746697-BCC4CC7D-1CA3-4E6C-ACE5-14DBD26C5CCE Q26748746-FBDFE246-211F-49C9-900E-19A901BFC317 Q27311393-D7B70FAB-3EA6-43C6-B6A0-8BAE34A6F473 Q28265144-06EB9824-FFD1-4C1A-8E4F-491FC4B80C8D Q28275605-C19B5C9D-2A63-4A0C-A862-FF30A2664249 Q28602250-AF03114C-E902-4A6C-85CA-7E7CC6AE081A Q31111222-6EC40F0F-5C6E-4485-8AD2-65AA8F20E91C Q33534742-B8C059D2-07DE-4D94-A93D-1B3F85A9B0DB Q33563703-011E31FF-1326-44AC-9AC6-B72987265E6F Q33620555-84D06D46-EF80-407C-9B57-43298EE93355 Q33852174-76101961-C5C9-480A-86A1-789D951DE463 Q34968138-8C75E070-85E6-4877-9EF8-D5CC2FB9B02E Q35147055-6DE02F4B-6E9F-4297-8CCA-84BF7D585CF1 Q36214158-ECA391CE-4B4B-4DDB-B3E8-87D5266F45D5 Q36844513-3C90A315-EDAC-4DFE-A8D2-D3670BEEB501 Q37398870-707208CB-1474-4725-829B-6DCA72458D93 Q37465544-12052221-67B6-42B8-9270-7360E487E342 Q37587370-8CBB9A55-CB3E-4514-A33A-8E445BBF12A4 Q37674711-EBD09805-86DF-4C7A-AECE-FC1B2CAE1149 Q37690732-8EBDBF10-5A64-43D6-98A9-1822B6233F1D Q37730995-A9D9FE3D-1034-4256-AD56-7B80E1D6548D Q38100846-9A773962-5EC1-4FF7-91E3-1FE4107C7892 Q38227972-442996B3-1531-4762-A896-755D39D8D848 Q38458846-1ABE7E1C-30B2-493B-8A88-DA3A4A53BF76 Q39218839-242B2405-42D2-402D-9FB9-9BB1A6E451A9 Q41399619-A62C6D2B-B224-4216-A8E3-19EA18736039 Q47108476-E0C1B8DC-576C-4FAF-84D5-188A5CD615A8 Q52552445-F6611E7E-7439-4E28-8504-B164008EA8B8 Q52594390-7EE1358C-7137-47F5-9A56-0733A2A33E92

P2860

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

http://www.wikidata.org/entity/Q34177087

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Development of Potential Pharm ...... n Systemic Lupus Erythematosus

@ast

Development of Potential Pharm ...... n Systemic Lupus Erythematosus

@en

Development of Potential Pharm ...... n Systemic Lupus Erythematosus

@nl

type

label

Development of Potential Pharm ...... n Systemic Lupus Erythematosus

@ast

Development of Potential Pharm ...... n Systemic Lupus Erythematosus

@en

Development of Potential Pharm ...... n Systemic Lupus Erythematosus

@nl

prefLabel

Development of Potential Pharm ...... n Systemic Lupus Erythematosus

@ast

Development of Potential Pharm ...... n Systemic Lupus Erythematosus

@en

Development of Potential Pharm ...... n Systemic Lupus Erythematosus

@nl

P1433

Q34177087-8281237B-71BB-4199-A184-84FE71869A52

P1476

Q34177087-D92BC3AE-966A-4AFB-ACCA-E9FCAF37DC51

P2093

Q34177087-095CA4E1-A6C4-4178-A8C2-956777A6EFA3

Q34177087-3BB5A14A-0027-466A-B936-2E375B236D1A

Q34177087-55FAFE0E-16CA-459F-B9DF-D4FF4F9E0AF6

Q34177087-6897E847-EFF9-4A3D-B262-C3E884E410F0

Q34177087-6C2CBB79-42B9-48E5-821D-8AEE8950BB1A

Q34177087-7A58C4C0-7EC3-437C-BFEE-FEDD50562A3B

Q34177087-B1790C6A-33AC-48F5-96BC-0DF8FBA70DB3

Q34177087-B1F2772A-0B73-4987-8F00-659107C0EE49

Q34177087-BF45ECAE-ABF0-44F0-901C-262F6A561C75

Q34177087-F67E90AF-C703-4175-99A9-4D5ED76C2C20

P2860

Q34177087-03D9EB49-4E83-416C-B741-1A2ADA602AFC

Q34177087-13138FE4-3A22-4661-921B-29F1BBF75AEC

Q34177087-231A6AC9-6C06-4C5F-BD36-1232E18A08DC

Q34177087-324C4BA6-8002-45EA-A18E-BD48415286EB

Q34177087-35A432FE-639C-4C63-B483-5AD787D8405F

Q34177087-39F4CD1E-6CDD-47B7-BE6B-A5B8B4304BDB

Q34177087-41764625-9775-4223-9388-B99D384D1F2B

Q34177087-47D2A654-AEA4-42FC-ACD5-7E15A9B34AF9

Q34177087-4D9FD1F6-5FAF-42B7-881C-352F70F96FE7

Q34177087-5DC4976D-283F-4E37-A89A-8C17670301B8

P304

Q34177087-3B0ED66D-ADB5-4ECA-9C46-5C0D54D22C5A

P31

Q34177087-0ABB30CF-8198-4308-A017-5A4D0F8DC863

P356

Q34177087-D203414E-B645-4493-94CE-F6A8823421A6

P478

Q34177087-486EF92C-270F-4E9C-B71A-881E09F96454

P577

Q34177087-83500DEF-D08C-4168-84BF-C52FD8109D79

P5875

Q34177087-16ED0956-F9A5-48B6-B504-50732004436A

P698

Q34177087-69C46971-F1CD-4403-B12B-FC142A832276

P921

Q34177087-14E7A02C-8A4C-408B-8414-A3124F8B0686

P932

Q34177087-7910284B-D57B-428E-84C1-0A7AF7BF33F9

P356

P1433

Human Genomics and Proteomics

P1476

Development of Potential Pharm ...... n Systemic Lupus Erythematosus

@en

P2093

Anthony J Coyle

http://www.w3.org/2001/XMLSchema#string

Bahija Jallal

http://www.w3.org/2001/XMLSchema#string

Barbara White

http://www.w3.org/2001/XMLSchema#string

Brandon W Higgs

http://www.w3.org/2001/XMLSchema#string

Chris Morehouse

http://www.w3.org/2001/XMLSchema#string

Jianliang Zhang

http://www.w3.org/2001/XMLSchema#string

Melissa de Los Reyes

http://www.w3.org/2001/XMLSchema#string

Peter A Kiener

http://www.w3.org/2001/XMLSchema#string

Philip Brohawn

http://www.w3.org/2001/XMLSchema#string

Wendy Trigona

http://www.w3.org/2001/XMLSchema#string

P2860

Phospholipid scramblase 1 potentiates the antiviral activity of interferon

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

Pharmacodynamic biomarkers for molecular cancer therapeutics

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

Data quality in genomics and microarrays.

Impact of microarray data quality on genomic data submissions to the FDA.

Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases.

Clinical biomarkers in drug discovery and development.

Type I interferon correlates with serological and clinical manifestations of SLE

P304

e3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4061/2009/374312

http://www.w3.org/2001/XMLSchema#string

P478

2009

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47430055

http://www.w3.org/2001/XMLSchema#string

P698

20948567

http://www.w3.org/2001/XMLSchema#string

P921

P932

2950308

http://www.w3.org/2001/XMLSchema#string